319 related articles for article (PubMed ID: 2040013)
1. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
Milner J; Medcalf EA
Cell; 1991 May; 65(5):765-74. PubMed ID: 2040013
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Milner J; Medcalf EA; Cook AC
Mol Cell Biol; 1991 Jan; 11(1):12-9. PubMed ID: 1986215
[TBL] [Abstract][Full Text] [Related]
3. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
[TBL] [Abstract][Full Text] [Related]
4. A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer.
Milner J
Proc Biol Sci; 1991 Aug; 245(1313):139-45. PubMed ID: 1682937
[TBL] [Abstract][Full Text] [Related]
5. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
Hainaut P; Milner J
Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
[TBL] [Abstract][Full Text] [Related]
6. Conversion of wild-type p53 core domain into a conformation that mimics a hot-spot mutant.
Ishimaru D; Maia LF; Maiolino LM; Quesado PA; Lopez PC; Almeida FC; Valente AP; Silva JL
J Mol Biol; 2003 Oct; 333(2):443-51. PubMed ID: 14529628
[TBL] [Abstract][Full Text] [Related]
7. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
8. The properties of p53 proteins selected for the loss of suppression of transformation.
Olson DC; Levine AJ
Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
[TBL] [Abstract][Full Text] [Related]
9. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
11. Specific DNA binding by different classes of human p53 mutants.
Rolley N; Butcher S; Milner J
Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
[TBL] [Abstract][Full Text] [Related]
12. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
[TBL] [Abstract][Full Text] [Related]
13. Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation.
Hainaut P; Milner J
EMBO J; 1992 Oct; 11(10):3513-20. PubMed ID: 1396554
[TBL] [Abstract][Full Text] [Related]
14. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
15. A human tumour-derived mutant p53 protein induces a p34cdc2 reversible growth arrest in fission yeast.
Wagner P; Simanis V; Maimets T; Keenan E; Addison C; Brain R; Grimaldi M; Sturzbecher HW; Jenkins J
Oncogene; 1991 Sep; 6(9):1539-47. PubMed ID: 1923520
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
17. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations in bladder carcinoma cell lines.
Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
[TBL] [Abstract][Full Text] [Related]
19. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
20. Conformational effects of environmentally induced, cancer-related mutations in the p53 protein.
Brandt-Rauf PW; Monaco R; Pincus MR
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9262-6. PubMed ID: 7937752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
